BLIS Technologies Limited is a pioneering organisation in the biopharmaceutical sector, founded on the innovative research of Professor John Tagg from the University of Otago, New Zealand. The company has gained recognition for its discovery of the oral probiotic strains, BLIS K12™ and BLIS M18™, which are backed by over 30 years of extensive research, including over 70 clinical trials. BLIS Technologies Ltd provides partners with both ingredient and finished products that focus on various health areas, notably immunity, oral health, and the health of teeth and gums.

Services include:
– Anatomical Therapeutic Chemical (ATC) Classification
– APIs (Active Pharmaceutical Ingredients)

BLIS Technologies Ltd continues to contribute significantly to the pharmaceutical industry by leveraging its expertise in probiotic research and product development. For more information, visit blis.co.nz.